Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: Data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia : Data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers. / Norgaard, Caroline Holm; Friedrich, Sarah; Hansen, Charlotte Thim; Gerds, Thomas; Ballard, Clive; Moller, Daniel Vega; Knudsen, Lotte Bjerre; Kvist, Kajsa; Zinman, Bernard; Holm, Ellen; Torp-Pedersen, Christian; Morch, Lina Steinrud.

In: Alzheimers & dementia-Translational research & clinical interventions, Vol. 8, No. 1, 12268, 2022.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Norgaard, CH, Friedrich, S, Hansen, CT, Gerds, T, Ballard, C, Moller, DV, Knudsen, LB, Kvist, K, Zinman, B, Holm, E, Torp-Pedersen, C & Morch, LS 2022, 'Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: Data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers', Alzheimers & dementia-Translational research & clinical interventions, vol. 8, no. 1, 12268. https://doi.org/10.1002/trc2.12268

APA

Norgaard, C. H., Friedrich, S., Hansen, C. T., Gerds, T., Ballard, C., Moller, D. V., Knudsen, L. B., Kvist, K., Zinman, B., Holm, E., Torp-Pedersen, C., & Morch, L. S. (2022). Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: Data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers. Alzheimers & dementia-Translational research & clinical interventions, 8(1), [12268]. https://doi.org/10.1002/trc2.12268

Vancouver

Norgaard CH, Friedrich S, Hansen CT, Gerds T, Ballard C, Moller DV et al. Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: Data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers. Alzheimers & dementia-Translational research & clinical interventions. 2022;8(1). 12268. https://doi.org/10.1002/trc2.12268

Author

Norgaard, Caroline Holm ; Friedrich, Sarah ; Hansen, Charlotte Thim ; Gerds, Thomas ; Ballard, Clive ; Moller, Daniel Vega ; Knudsen, Lotte Bjerre ; Kvist, Kajsa ; Zinman, Bernard ; Holm, Ellen ; Torp-Pedersen, Christian ; Morch, Lina Steinrud. / Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia : Data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers. In: Alzheimers & dementia-Translational research & clinical interventions. 2022 ; Vol. 8, No. 1.

Bibtex

@article{44edaa37999a43d7b0505ed18cda3601,
title = "Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: Data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers",
abstract = "IntroductionPeople with type 2 diabetes have increased risk of dementia. Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) are among the promising therapies for repurposing as a treatment for Alzheimer's disease; a key unanswered question is whether they reduce dementia incidence in people with type 2 diabetes. MethodsWe assessed exposure to GLP-1 RAs in patients with type 2 diabetes and subsequent diagnosis of dementia in two large data sources with long-term follow-up: pooled data from three randomized double-blind placebo-controlled cardiovascular outcome trials (15,820 patients) and a nationwide Danish registry-based cohort (120,054 patients). ResultsDementia rate was lower both in patients randomized to GLP-1 RAs versus placebo (hazard ratio [HR]: 0.47 (95% confidence interval [CI]: 0.25-0.86) and in the nationwide cohort (HR: 0.89; 95% CI: 0.86-0.93 with yearly increased exposure to GLP-1 RAs). DiscussionTreatment with GLP-1 RAs may provide a new opportunity to reduce the incidence of dementia in patients with type 2 diabetes.",
keywords = "dementia, glucagon-like peptide-1 receptor agonists, randomized controlled trial, real-world evidence, type 2 diabetes, CARDIOVASCULAR OUTCOMES, MOUSE MODEL, LIRAGLUTIDE, SEMAGLUTIDE",
author = "Norgaard, {Caroline Holm} and Sarah Friedrich and Hansen, {Charlotte Thim} and Thomas Gerds and Clive Ballard and Moller, {Daniel Vega} and Knudsen, {Lotte Bjerre} and Kajsa Kvist and Bernard Zinman and Ellen Holm and Christian Torp-Pedersen and Morch, {Lina Steinrud}",
year = "2022",
doi = "10.1002/trc2.12268",
language = "English",
volume = "8",
journal = "Alzheimers & dementia-Translational research & clinical interventions",
publisher = "Wiley-Interscience",
number = "1",

}

RIS

TY - JOUR

T1 - Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia

T2 - Data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers

AU - Norgaard, Caroline Holm

AU - Friedrich, Sarah

AU - Hansen, Charlotte Thim

AU - Gerds, Thomas

AU - Ballard, Clive

AU - Moller, Daniel Vega

AU - Knudsen, Lotte Bjerre

AU - Kvist, Kajsa

AU - Zinman, Bernard

AU - Holm, Ellen

AU - Torp-Pedersen, Christian

AU - Morch, Lina Steinrud

PY - 2022

Y1 - 2022

N2 - IntroductionPeople with type 2 diabetes have increased risk of dementia. Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) are among the promising therapies for repurposing as a treatment for Alzheimer's disease; a key unanswered question is whether they reduce dementia incidence in people with type 2 diabetes. MethodsWe assessed exposure to GLP-1 RAs in patients with type 2 diabetes and subsequent diagnosis of dementia in two large data sources with long-term follow-up: pooled data from three randomized double-blind placebo-controlled cardiovascular outcome trials (15,820 patients) and a nationwide Danish registry-based cohort (120,054 patients). ResultsDementia rate was lower both in patients randomized to GLP-1 RAs versus placebo (hazard ratio [HR]: 0.47 (95% confidence interval [CI]: 0.25-0.86) and in the nationwide cohort (HR: 0.89; 95% CI: 0.86-0.93 with yearly increased exposure to GLP-1 RAs). DiscussionTreatment with GLP-1 RAs may provide a new opportunity to reduce the incidence of dementia in patients with type 2 diabetes.

AB - IntroductionPeople with type 2 diabetes have increased risk of dementia. Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) are among the promising therapies for repurposing as a treatment for Alzheimer's disease; a key unanswered question is whether they reduce dementia incidence in people with type 2 diabetes. MethodsWe assessed exposure to GLP-1 RAs in patients with type 2 diabetes and subsequent diagnosis of dementia in two large data sources with long-term follow-up: pooled data from three randomized double-blind placebo-controlled cardiovascular outcome trials (15,820 patients) and a nationwide Danish registry-based cohort (120,054 patients). ResultsDementia rate was lower both in patients randomized to GLP-1 RAs versus placebo (hazard ratio [HR]: 0.47 (95% confidence interval [CI]: 0.25-0.86) and in the nationwide cohort (HR: 0.89; 95% CI: 0.86-0.93 with yearly increased exposure to GLP-1 RAs). DiscussionTreatment with GLP-1 RAs may provide a new opportunity to reduce the incidence of dementia in patients with type 2 diabetes.

KW - dementia

KW - glucagon-like peptide-1 receptor agonists

KW - randomized controlled trial

KW - real-world evidence

KW - type 2 diabetes

KW - CARDIOVASCULAR OUTCOMES

KW - MOUSE MODEL

KW - LIRAGLUTIDE

KW - SEMAGLUTIDE

U2 - 10.1002/trc2.12268

DO - 10.1002/trc2.12268

M3 - Journal article

C2 - 35229024

VL - 8

JO - Alzheimers & dementia-Translational research & clinical interventions

JF - Alzheimers & dementia-Translational research & clinical interventions

IS - 1

M1 - 12268

ER -

ID: 333611482